Article info

Download PDFPDF

Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease
  1. Correspondence to:
    Dr J Sträter
    Department of Pathology, University of Ulm, Albert-Einstein-Allee 11, 89081 Ulm, Germany; joern.straetermedizin.uni-ulm.de
View Full Text

Citation

Sträter J, Hinz U, Hasel C, et al
Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease

Publication history

  • Accepted November 9, 2004
  • Revised October 27, 2004
  • First published April 14, 2005.
Online issue publication 
April 14, 2005

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.